<?xml version='1.0' encoding='utf-8'?>
<document id="27747728"><sentence text="Colchicine-Induced Acute Neuromyopathy in a Patient Using Concomitant Fluconazole: Case Report and Literature Review."><entity charOffset="70-81" id="DDI-PubMed.27747728.s1.e0" text="Fluconazole" /></sentence><sentence text="A 54-year-old woman presented at the emergency department after experiencing lower limb weakness and bilateral ankle pain for 2 days" /><sentence text=" She had a history of type 2 diabetes mellitus, diabetes mellitus nephropathy with chronic kidney disease, and chronic gouty arthritis" /><sentence text=" She had received 0" /><sentence text="6 mg colchicine orally once or twice daily for 8 months"><entity charOffset="5-15" id="DDI-PubMed.27747728.s5.e0" text="colchicine" /></sentence><sentence text=" Four days prior to her emergency department visit, she was discharged from our nephrology ward, where she had been admitted because of a urinary tract infection" /><sentence text=" During hospitalization, she was treated with intravenous cefazolin for 7 days"><entity charOffset="58-67" id="DDI-PubMed.27747728.s7.e0" text="cefazolin" /></sentence><sentence text=" Because of persistent symptoms, we performed repeated urinalysis, which revealed the presence of yeast" /><sentence text=" She was diagnosed with fungal cystitis, and was administered a 7-day course of once-daily oral fluconazole (100 mg)"><entity charOffset="96-107" id="DDI-PubMed.27747728.s9.e0" text="fluconazole" /></sentence><sentence text=" On day 5 of the course, she was discharged and asked to continue taking oral colchicine (0"><entity charOffset="78-88" id="DDI-PubMed.27747728.s10.e0" text="colchicine" /></sentence><sentence text="6 mg, twice daily), as well as fluconazole for the full 7-day course"><entity charOffset="31-42" id="DDI-PubMed.27747728.s11.e0" text="fluconazole" /></sentence><sentence text=" Neurological examination revealed marked symmetrical weakness (Medical Research Council grade 4/5)" /><sentence text=" Her sensation and coordination were intact" /><sentence text=" Initial laboratory investigation revealed hyperkalemia (6" /><sentence text="2 mmol/L), and blood urea nitrogen, serum creatinine, and creatine kinase levels of 181, 11"><entity charOffset="21-34" id="DDI-PubMed.27747728.s15.e0" text="urea nitrogen" /><entity charOffset="42-52" id="DDI-PubMed.27747728.s15.e1" text="creatinine" /><entity charOffset="58-66" id="DDI-PubMed.27747728.s15.e2" text="creatine" /><pair ddi="false" e1="DDI-PubMed.27747728.s15.e0" e2="DDI-PubMed.27747728.s15.e0" /><pair ddi="false" e1="DDI-PubMed.27747728.s15.e0" e2="DDI-PubMed.27747728.s15.e1" /><pair ddi="false" e1="DDI-PubMed.27747728.s15.e0" e2="DDI-PubMed.27747728.s15.e2" /><pair ddi="false" e1="DDI-PubMed.27747728.s15.e1" e2="DDI-PubMed.27747728.s15.e1" /><pair ddi="false" e1="DDI-PubMed.27747728.s15.e1" e2="DDI-PubMed.27747728.s15.e2" /></sentence><sentence text="16 mg/dL, and 803 U/L respectively" /><sentence text=" Her liver function tests showed elevated alanine aminotransferase levels (112 U/L)"><entity charOffset="42-49" id="DDI-PubMed.27747728.s17.e0" text="alanine" /></sentence><sentence text=" Electromyographic results were consistent with colchicine neuromyopathy"><entity charOffset="48-58" id="DDI-PubMed.27747728.s18.e0" text="colchicine" /></sentence><sentence text=" Ten days after treatment cessation, muscle enzyme levels normalized and weakness gradually disappeared" /><sentence text=" We used the Drug Interaction Probability Scale to evaluate our patient's case" /><sentence text=" A score of 5 was calculated, indicating that the drug-drug interaction was the probable cause of neuromuscular toxicity" /><sentence text="" /></document>